The use of antibodies against the IL-2 receptor in transplantation

Curr Opin Immunol. 1998 Oct;10(5):507-12. doi: 10.1016/s0952-7915(98)80215-x.


Humanized monoclonal antibodies that recognize the alpha chain of the IL-2 receptor (e.g. daclizumab) have been used to prevent allograft rejection, since this chain is expressed by T cells participating in allograft rejection but not by resting T cells. In a randomized trial, when added to standard cyclosporin-based immunosuppression, daclizumab significantly reduced the frequency of acute rejection of renal transplants.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Clinical Trials as Topic
  • DNA-Binding Proteins / genetics
  • Daclizumab
  • Graft Rejection / prevention & control*
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Immunotherapy
  • Receptors, Interleukin-2 / immunology*
  • Receptors, Interleukin-2 / physiology
  • STAT4 Transcription Factor
  • Trans-Activators / genetics


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • DNA-Binding Proteins
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Interleukin-2
  • STAT4 Transcription Factor
  • STAT4 protein, human
  • Trans-Activators
  • Daclizumab